恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

70-ag捕鱼平台

文字: 2017-9-28    浏览次数:903    

purpose patients with breast cancer liver metastasis have a poor prognosis. local therapy for liver metastasis increases survival.the purpose of this pilot prospective study was to evaluate the efficacy andsafety of doxorubicin drug-eluting beads chemoembolization for liver-dominantbreast cancer metastasis (ldbm) refractory to chemotherapy.


目的:乳腺癌肝转移患者预后较差。局部治疗肝转移可增加患者生存率。该前瞻性研究的目的是评估阿霉素deb-tace治疗化疗耐受的以肝为主乳腺癌转移(ldbm)的疗效与安全性。

materials and methods all patients with ldbm refractory to oftwo or more lines of systemic chemotherapy were screened. two chemoembolizations at 1-month intervals were scheduled for each patient. tumor responses were evaluated by mri every 3 months until progression or death. adverseevents were recorded according to the common terminology criteria for adverseevents (ctcae version 4.02) 1 month after each chemoembolization. all patients were free from systemic treatment until progression. patients with hormone-positivereceptors and/or her-positive disease status continued their targeted therapy.

材料与方法:对≥2线全身化疗耐受的ldbm患者进行筛选。每例患者均进行两次化疗栓塞,间隔时间为1个月。mri评估疗效,每3个月一次,直至肿瘤进展或患者死亡。在每次化疗栓塞1个月后,根据不良事件常用术语标准(ctcae 4.02版),记录不良事件的发生情况。所有患者均无系统性治疗,直至疾病进展。激素受体阳性和/或her阳性的患者继续靶向治疗。

results out of 23 patients enrolled (mean age:57.5±11.5 years), 17 completed two chemoembolizations and six underwent only one because of severe adverse events. at 3-month follow-up,the disease control rate was 83 %. the median progression-free survival from the first chemoembolization was 8 months, and the median overall survivalwas 17 months. nineteen patients remained free from any systemic chemotherapy for a mean of 209 ± 92 days until progression. eight grade 3 (asthenia n = 3, anemia n = 2,thrombocythemia n = 2, liver toxicity n = 1) (rev 1comment 1) occurred after the first procedure. no patientdied directly due to the procedure.

结果:入组23例患者,平均年龄为57.5±11.5岁。17例完成两次化疗栓塞,6例因严重不良事件仅完成一次化疗栓塞。随访3个月时,疾病控制率达83%。自第一次化疗栓塞起,中位pfs为8个月,中位os为17个月。19例患者平均209±92天未进行任何全身性化疗直至疾病进展。第一次术后有8例发生3级不良反应(乏力:n=3,贫血:n=2,血小板增多:n=2,肝脏毒性:n=1)。因手术导致的直接死亡例数为0。

conclusionwhile chemoembolization with doxorubicin eluding beads for refractory ldbm leads to an 83 % disease control rate, it also causes severe side effects that need to be adequately managed.

结论:应用阿霉素deb-tace治疗难治性ldbm,可实现83%的疾病控制率,但也会出现严重不良反应,需要适当管理。